萨奎比利/阿利沙坦与奥美沙坦在血压不降型高血压患者中的降压效果

IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE
Wei Zhang, Jie Yan, Jin Zhang, Qian Ge, Xiao-Hong Lu, Shao-Xing Chen, Wen-Jie Xu, Jing-Chao Sun, Jin-Feng Li, Zi-Chen Liu, Qiang Wang, Xiang-Nan Zhou, Yan Li, Ji-Guang Wang
{"title":"萨奎比利/阿利沙坦与奥美沙坦在血压不降型高血压患者中的降压效果","authors":"Wei Zhang, Jie Yan, Jin Zhang, Qian Ge, Xiao-Hong Lu, Shao-Xing Chen, Wen-Jie Xu, Jing-Chao Sun, Jin-Feng Li, Zi-Chen Liu, Qiang Wang, Xiang-Nan Zhou, Yan Li, Ji-Guang Wang","doi":"10.1097/HJH.0000000000004065","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Abnormal nocturnal blood pressure dipping profile is an important cardiovascular risk factor in patients with hypertension. This analysis aimed to investigate the effects of Sacubitril/Allisartan on blood pressure in Chinese patients with mild to moderate hypertension and a nighttime nondipping pattern.</p><p><strong>Methods: </strong>We performed analysis of data from a randomized clinical trial that compared the blood pressure-lowering effect at 12 weeks of treatment with Sacubitril/Allisartan (240 or 480 mg/day) and Olmesartan (20 mg/day). Nighttime nondipping pattern was defined as mean nighttime (10 p.m. to 6 a.m.) ambulatory blood pressure fall of less than 10% versus daytime (6 a.m. to 10 p.m.) ambulatory blood pressure. The outcome measures included clinical and 24-h, daytime, and nighttime ambulatory blood pressure.</p><p><strong>Results: </strong>Of the 1197 randomized patients of the trial, 497 (41.5%) patients had a nighttime nondipping pattern and were included in this analysis. At 12 weeks, the least square mean (±standard error) changes from baseline in 24-h mean ambulatory SBP/DBP (maSBP/maDBP) in the Sacubitril/Allisartan 240 and 480 mg/day groups were -10.3 ± 1.1/-5.3 ± 0.6 and -13.7 ± 1.1/-6.7 ± 0.6 mmHg, respectively. The reductions in nighttime maSBP were significantly greater with both doses of Sacubitril/Allisartan compared with Olmesartan 20 mg [-12.7 ± 1.2/6.3 ± 0.7 mmHg, with a difference of -3.8 (-7.2 to -0.4) mmHg, P = 0.029 for Sacubitril/Allisartan 240 mg and -7.5 (-10.9 to -4.1) mmHg, P < 0.001 for Sacubitril/Allisartan 480 mg]. The 24-h mean ambulatory blood pressure and nighttime maSBP reductions in nondipper patients tended to be dose-dependent for Sacubitril/Allisartan. At 12 weeks of treatment, the prevalence of dippers was significantly (P ≤ 0.019) higher in the Sacubitril/Allisartan 240 and 480 mg groups than in the Olmesartan 20 mg group for both SBP (46.9 and 47.9 versus 33.7%) and DBP (42.0 and 40.2 versus 26.5%).</p><p><strong>Conclusion: </strong>Sacubitril/Allisartan is particularly effective in reducing nighttime blood pressure and in reversing the nondipping to dipping nighttime blood pressure pattern.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Blood pressure-lowering efficacy of Sacubitril/Allisartan versus Olmesartan in Chinese hypertensive patients with a nondipping blood pressure pattern.\",\"authors\":\"Wei Zhang, Jie Yan, Jin Zhang, Qian Ge, Xiao-Hong Lu, Shao-Xing Chen, Wen-Jie Xu, Jing-Chao Sun, Jin-Feng Li, Zi-Chen Liu, Qiang Wang, Xiang-Nan Zhou, Yan Li, Ji-Guang Wang\",\"doi\":\"10.1097/HJH.0000000000004065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Abnormal nocturnal blood pressure dipping profile is an important cardiovascular risk factor in patients with hypertension. This analysis aimed to investigate the effects of Sacubitril/Allisartan on blood pressure in Chinese patients with mild to moderate hypertension and a nighttime nondipping pattern.</p><p><strong>Methods: </strong>We performed analysis of data from a randomized clinical trial that compared the blood pressure-lowering effect at 12 weeks of treatment with Sacubitril/Allisartan (240 or 480 mg/day) and Olmesartan (20 mg/day). Nighttime nondipping pattern was defined as mean nighttime (10 p.m. to 6 a.m.) ambulatory blood pressure fall of less than 10% versus daytime (6 a.m. to 10 p.m.) ambulatory blood pressure. The outcome measures included clinical and 24-h, daytime, and nighttime ambulatory blood pressure.</p><p><strong>Results: </strong>Of the 1197 randomized patients of the trial, 497 (41.5%) patients had a nighttime nondipping pattern and were included in this analysis. At 12 weeks, the least square mean (±standard error) changes from baseline in 24-h mean ambulatory SBP/DBP (maSBP/maDBP) in the Sacubitril/Allisartan 240 and 480 mg/day groups were -10.3 ± 1.1/-5.3 ± 0.6 and -13.7 ± 1.1/-6.7 ± 0.6 mmHg, respectively. The reductions in nighttime maSBP were significantly greater with both doses of Sacubitril/Allisartan compared with Olmesartan 20 mg [-12.7 ± 1.2/6.3 ± 0.7 mmHg, with a difference of -3.8 (-7.2 to -0.4) mmHg, P = 0.029 for Sacubitril/Allisartan 240 mg and -7.5 (-10.9 to -4.1) mmHg, P < 0.001 for Sacubitril/Allisartan 480 mg]. The 24-h mean ambulatory blood pressure and nighttime maSBP reductions in nondipper patients tended to be dose-dependent for Sacubitril/Allisartan. At 12 weeks of treatment, the prevalence of dippers was significantly (P ≤ 0.019) higher in the Sacubitril/Allisartan 240 and 480 mg groups than in the Olmesartan 20 mg group for both SBP (46.9 and 47.9 versus 33.7%) and DBP (42.0 and 40.2 versus 26.5%).</p><p><strong>Conclusion: </strong>Sacubitril/Allisartan is particularly effective in reducing nighttime blood pressure and in reversing the nondipping to dipping nighttime blood pressure pattern.</p>\",\"PeriodicalId\":16043,\"journal\":{\"name\":\"Journal of Hypertension\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/HJH.0000000000004065\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HJH.0000000000004065","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

背景:夜间血压下降异常是高血压患者重要的心血管危险因素。本分析旨在探讨Sacubitril/Allisartan对中国轻度至中度高血压患者夜间不浸渍模式血压的影响。方法:我们对一项随机临床试验的数据进行了分析,该试验比较了Sacubitril/Allisartan(240或480 mg/天)和Olmesartan (20 mg/天)治疗12周时的降压效果。夜间不下降模式定义为夜间(晚上10点至早上6点)平均动态血压与白天(早上6点至晚上10点)动态血压相比下降小于10%。结果测量包括临床和24小时、白天和夜间动态血压。结果:在试验的1197例随机患者中,497例(41.5%)患者有夜间不浸尿模式,并被纳入本分析。12周时,Sacubitril/Allisartan 240和480 mg/d组24小时平均动态收缩压/舒张压(maSBP/maDBP)相对基线的最小二乘平均值(±标准误差)变化分别为-10.3±1.1/-5.3±0.6和-13.7±1.1/-6.7±0.6 mmHg。与奥美沙坦20 mg[-12.7±1.2/6.3±0.7 mmHg]相比,两种剂量的Sacubitril/Allisartan夜间maSBP的降低显著更大,差异为-3.8(-7.2至-0.4)mmHg, Sacubitril/Allisartan 240 mg和-7.5(-10.9至-4.1)mmHg, P = 0.029, P结论:Sacubitril/Allisartan在降低夜间血压和扭转夜间血压不降向降的模式方面特别有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Blood pressure-lowering efficacy of Sacubitril/Allisartan versus Olmesartan in Chinese hypertensive patients with a nondipping blood pressure pattern.

Background: Abnormal nocturnal blood pressure dipping profile is an important cardiovascular risk factor in patients with hypertension. This analysis aimed to investigate the effects of Sacubitril/Allisartan on blood pressure in Chinese patients with mild to moderate hypertension and a nighttime nondipping pattern.

Methods: We performed analysis of data from a randomized clinical trial that compared the blood pressure-lowering effect at 12 weeks of treatment with Sacubitril/Allisartan (240 or 480 mg/day) and Olmesartan (20 mg/day). Nighttime nondipping pattern was defined as mean nighttime (10 p.m. to 6 a.m.) ambulatory blood pressure fall of less than 10% versus daytime (6 a.m. to 10 p.m.) ambulatory blood pressure. The outcome measures included clinical and 24-h, daytime, and nighttime ambulatory blood pressure.

Results: Of the 1197 randomized patients of the trial, 497 (41.5%) patients had a nighttime nondipping pattern and were included in this analysis. At 12 weeks, the least square mean (±standard error) changes from baseline in 24-h mean ambulatory SBP/DBP (maSBP/maDBP) in the Sacubitril/Allisartan 240 and 480 mg/day groups were -10.3 ± 1.1/-5.3 ± 0.6 and -13.7 ± 1.1/-6.7 ± 0.6 mmHg, respectively. The reductions in nighttime maSBP were significantly greater with both doses of Sacubitril/Allisartan compared with Olmesartan 20 mg [-12.7 ± 1.2/6.3 ± 0.7 mmHg, with a difference of -3.8 (-7.2 to -0.4) mmHg, P = 0.029 for Sacubitril/Allisartan 240 mg and -7.5 (-10.9 to -4.1) mmHg, P < 0.001 for Sacubitril/Allisartan 480 mg]. The 24-h mean ambulatory blood pressure and nighttime maSBP reductions in nondipper patients tended to be dose-dependent for Sacubitril/Allisartan. At 12 weeks of treatment, the prevalence of dippers was significantly (P ≤ 0.019) higher in the Sacubitril/Allisartan 240 and 480 mg groups than in the Olmesartan 20 mg group for both SBP (46.9 and 47.9 versus 33.7%) and DBP (42.0 and 40.2 versus 26.5%).

Conclusion: Sacubitril/Allisartan is particularly effective in reducing nighttime blood pressure and in reversing the nondipping to dipping nighttime blood pressure pattern.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Hypertension
Journal of Hypertension 医学-外周血管病
CiteScore
7.90
自引率
6.10%
发文量
1389
审稿时长
3 months
期刊介绍: The Journal of Hypertension publishes papers reporting original clinical and experimental research which are of a high standard and which contribute to the advancement of knowledge in the field of hypertension. The Journal publishes full papers, reviews or editorials (normally by invitation), and correspondence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信